Polio Pipeline Review, H2 2015
Summary
Global Markets Directs, Polio Pipeline Review, H2 2015, provides an overview of the Polios therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Polio
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Polio
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Polio Overview 9
Therapeutics Development 10
Pipeline Products for Polio - Overview 10
Pipeline Products for Polio - Comparative Analysis 11
Polio - Therapeutics under Development by Companies 12
Polio - Therapeutics under Investigation by Universities/Institutes 14
Polio - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Polio - Products under Development by Companies 18
Polio - Products under Investigation by Universities/Institutes 19
Polio - Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co., Ltd 20
Beijing Tiantan Biological Products Co., Ltd. 21
Bharat Biotech International Limited 22
Biological E. Limited 23
Boryung Pharmaceutical Co., Ltd. 24
Codagenix, Inc. 25
Crucell N.V. 26
Daiichi Sankyo Company, Limited 27
Grifols, S.A. 28
Panacea Biotec Limited 29
Sanofi Pasteur SA 30
Sentinext Therapeutics Sdn Bhd 31
Sinovac Biotech Ltd. 32
Taiga Biotechnologies, Inc. 33
Polio - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
immune globulin (human) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
IPVGVI-3000 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
polio (bivalent) virus like particle vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
polio (monovalent) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
polio [sabin] vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
polio vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
polio vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
polio vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
polio vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
polio vaccine [types 1, 2, 3] (monovalent) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
poliomyelitis vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PR-5I - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Protein for Oncology and Infectious Disease - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VN-0105 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Polio - Recent Pipeline Updates 64
Polio - Dormant Projects 65
Polio - Discontinued Products 66
Polio - Product Development Milestones 67
Featured News & Press Releases 67
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69
List Of Tables
Number of Products under Development for Polio, H2 2015 10
Number of Products under Development for Polio - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Polio - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 20
Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015 21
Polio - Pipeline by Bharat Biotech International Limited, H2 2015 22
Polio - Pipeline by Biological E. Limited, H2 2015 23
Polio - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015 24
Polio - Pipeline by Codagenix, Inc., H2 2015 25
Polio - Pipeline by Crucell N.V., H2 2015 26
Polio - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 27
Polio - Pipeline by Grifols, S.A., H2 2015 28
Polio - Pipeline by Panacea Biotec Limited, H2 2015 29
Polio - Pipeline by Sanofi Pasteur SA, H2 2015 30
Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2015 31
Polio - Pipeline by Sinovac Biotech Ltd., H2 2015 32
Polio - Pipeline by Taiga Biotechnologies, Inc., H2 2015 33
Assessment by Monotherapy Products, H2 2015 34
Assessment by Combination Products, H2 2015 35
Number of Products by Stage and Target, H2 2015 37
Number of Products by Stage and Route of Administration, H2 2015 39
Number of Products by Stage and Molecule Type, H2 2015 41
Polio Therapeutics - Recent Pipeline Updates, H2 2015 64
Polio - Dormant Projects, H2 2015 65
Polio - Discontinued Products, H2 2015 66
List Of Figures
Number of Products under Development for Polio, H2 2015 10
Number of Products under Development for Polio - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 34
Assessment by Combination Products, H2 2015 35
Number of Products by Targets, H2 2015 36
Number of Products by Stage and Targets, H2 2015 36
Number of Products by Routes of Administration, H2 2015 38
Number of Products by Stage and Routes of Administration, H2 2015 38
Number of Products by Molecule Types, H2 2015 40
Number of Products by Stage and Molecule Types, H2 2015 40
